OR51E2

Across TCGA pan-cancer cohorts, OR51E2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated OR51E2 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher OR51E2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR51E2 expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCEC show a favorable association.

ESCA, LUAD, and LUSC are the cancer types where OR51E2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.136	0.703	<.001	24	view →
LUAD	OS	Median	III,IV	0.180	0.689	.002	12	view →
LUSC	OS	Median	III,IV	0.211	0.575	.020	9	view →
SKCM	OS	Median	II,III,IV	0.672	0.342	.028	7	view →
CESC	OS	Median	II,III,IV	0.203	0.759	.021	6	view →
HNSC	OS	Median	All	0.187	0.685	.042	6	view →
LGG	DFS	Median	All	0.077	0.845	<.001	3	view →
UCEC	DFS	Median	All	0.930	0.626	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

OR51E2–ESCA (OS)

Open the ESCA breakdown →